PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Despite targeting an indication with a very small population, PTC Therapeutics has fully enrolled a pivotal trial for ataluren (PTC124), its potential disease-modifying therapy for Duchenne muscular dystrophy, and expects to produce top-line data early next year. Regulatory filings in the U.S. and EU could follow closely if the data are promising
You may also be interested in...
Faster Pace For Duchenne MD Research
Six-minute walk test proves itself in boys’ genetic disease, too.
PTC Taps Genzyme’s Global Reach, Pocketbook In Ultra-orphan Licensing Deal
PTC124 offers new approach for treating lysosomal storage disorders central to Genzyme’s success, as well as other genetic diseases.
PTC Advances Cystic Fibrosis Candidate On Encouraging Data
Company is pursuing PTC124 in nonsense-mutation-mediated CF, a patient population of about 3,000 in the U.S.